International Scholarly Research Notices

Review Article

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib

Figure 1

Forest plots showing ACR 20 response and DAS 28-4 ESR < 2.6 at month 3 and 6 with Tofacitinib 5 mg and 10 mg twice daily.
357904.fig.001a
(a) ACR 20 response at month 3 (Tofacitinib 5 mg)
357904.fig.001b
(b) ACR 20 response at month 6 (Tofacitinib 5 mg)
357904.fig.001c
(c) ACR 20 response at month 3 (Tofacitinib 10 mg)
357904.fig.001d
(d) ACR 20 response at month 6 (Tofacitinib 10 mg)
357904.fig.001e
(e) DAS 28-4 ESR < 2.6 at month 3 (Tofacitinib 5 mg)
357904.fig.001f
(f) DAS 28-4 ESR < 2.6 at month 6 (Tofacitinib 5 mg)
357904.fig.001g
(g) DAS 28-4 ESR < 2.6 at month 3 (Tofacitinib 10 mg)
357904.fig.001h
(h) DAS 28-4 ESR < 2.6 at month 6 (Tofacitinib 10 mg)